[go: up one dir, main page]

MX2017010053A - Soluciones radiofarmaceuticas con propiedades ventajosas. - Google Patents

Soluciones radiofarmaceuticas con propiedades ventajosas.

Info

Publication number
MX2017010053A
MX2017010053A MX2017010053A MX2017010053A MX2017010053A MX 2017010053 A MX2017010053 A MX 2017010053A MX 2017010053 A MX2017010053 A MX 2017010053A MX 2017010053 A MX2017010053 A MX 2017010053A MX 2017010053 A MX2017010053 A MX 2017010053A
Authority
MX
Mexico
Prior art keywords
advantageous properties
nuclide
radiopharmaceutical
radiopharmaceutical solutions
solutions
Prior art date
Application number
MX2017010053A
Other languages
English (en)
Other versions
MX369632B (es
Inventor
Hartvig Larsen Roy
Original Assignee
Sciencons AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15156714.6A external-priority patent/EP3061464B1/en
Priority claimed from US14/632,849 external-priority patent/US9433690B1/en
Application filed by Sciencons AS filed Critical Sciencons AS
Publication of MX2017010053A publication Critical patent/MX2017010053A/es
Publication of MX369632B publication Critical patent/MX369632B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones radiofarmacéuticas que comprenden el núclido madre 224Ra, su núclido descendiente 212Pb, y un agente complejante que forma complejos con el núclido descendiente; el uso de depuradores de quelatos focalizados para el núclido descendiente 224Ra, abre la posibilidad del uso de soluciones basadas en 224Ra para tratamientos médicos.
MX2017010053A 2015-02-26 2016-02-24 Soluciones radiofarmaceuticas con propiedades ventajosas. MX369632B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15156714.6A EP3061464B1 (en) 2015-02-26 2015-02-26 Radiopharmaceutical solutions with advantageous properties
US14/632,849 US9433690B1 (en) 2015-02-26 2015-02-26 Radiopharmaceutical solutions with advantageous properties
PCT/EP2016/053874 WO2016135200A1 (en) 2015-02-26 2016-02-24 Radiopharmaceutical solutions with advantageous properties

Publications (2)

Publication Number Publication Date
MX2017010053A true MX2017010053A (es) 2018-05-04
MX369632B MX369632B (es) 2019-11-14

Family

ID=55446768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010053A MX369632B (es) 2015-02-26 2016-02-24 Soluciones radiofarmaceuticas con propiedades ventajosas.

Country Status (16)

Country Link
EP (1) EP3261681B1 (es)
JP (2) JP6442072B2 (es)
KR (1) KR102630614B1 (es)
CN (1) CN107530456B (es)
AU (1) AU2016223475B2 (es)
CA (1) CA2973644C (es)
DK (1) DK3261681T3 (es)
ES (1) ES2784684T3 (es)
IL (1) IL253815B (es)
MX (1) MX369632B (es)
PH (1) PH12017501519A1 (es)
RU (1) RU2741794C2 (es)
SG (1) SG11201706849SA (es)
UA (1) UA122405C2 (es)
WO (1) WO2016135200A1 (es)
ZA (1) ZA201705301B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201706849SA (en) * 2015-02-26 2017-09-28 Sciencons AS Radiopharmaceutical solutions with advantageous properties
US9433690B1 (en) 2015-02-26 2016-09-06 Sciencons AS Radiopharmaceutical solutions with advantageous properties
US11306038B2 (en) * 2016-06-24 2022-04-19 Sciencons AS Preparation of 212Pb labeled monoclonal antibodies
EP3498308B1 (en) 2017-12-13 2024-11-27 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
ES2934984T3 (es) * 2020-02-13 2023-02-28 Orano Med Procedimiento para la modificación específica del sitio de un anticuerpo
EP4213826A1 (en) * 2020-09-15 2023-07-26 Oncoinvent AS Preparations of radium-224 and progenies for use in radionuclide therapy in combination with dna repair inhibitors
JP2024520180A (ja) * 2021-05-21 2024-05-21 ノーススター メディカル テクノロジーズ リミテッド ライアビリティ カンパニー ウロキナーゼプラスミノーゲンアクチベーター受容体標的放射性医薬品
CN116741428A (zh) * 2023-07-03 2023-09-12 西安迈斯拓扑科技有限公司 基于加速器辐照226Ra同时制备225Ac和212Pb的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720989B2 (ja) * 1988-05-25 1995-03-08 アメリカ合衆国 大環状キレート化合物の抱合体と診断的テスト方法
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
US20030228256A1 (en) * 2002-06-11 2003-12-11 Inverardi Luca A. Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations
EA020542B1 (ru) * 2004-02-20 2014-12-30 Алгета Ас Альфа-излучающие частицы гидроксиапатита
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
WO2012032043A1 (en) * 2010-09-07 2012-03-15 Areva Med Llc 212 pb imaging
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
ES2741643T3 (es) * 2013-06-07 2020-02-11 Nordic Nanovector Asa Terapia de combinación que comprende un anticuerpo anti-CD20 y el anticuerpo monoclonal HH1 radiomarcado
SG11201706849SA (en) * 2015-02-26 2017-09-28 Sciencons AS Radiopharmaceutical solutions with advantageous properties

Also Published As

Publication number Publication date
JP2018506574A (ja) 2018-03-08
NZ733742A (en) 2024-07-05
JP2019059747A (ja) 2019-04-18
CA2973644A1 (en) 2016-09-01
IL253815A0 (en) 2017-09-28
DK3261681T3 (da) 2020-04-27
AU2016223475B2 (en) 2021-04-08
EP3261681B1 (en) 2020-01-15
JP6734350B2 (ja) 2020-08-05
CN107530456A (zh) 2018-01-02
RU2741794C2 (ru) 2021-01-28
WO2016135200A1 (en) 2016-09-01
JP6442072B2 (ja) 2018-12-19
CA2973644C (en) 2023-09-19
ES2784684T3 (es) 2020-09-29
RU2017127720A3 (es) 2019-09-05
KR20170129788A (ko) 2017-11-27
CN107530456B (zh) 2021-02-26
AU2016223475A1 (en) 2017-08-03
PH12017501519B1 (en) 2018-02-05
MX369632B (es) 2019-11-14
EP3261681A1 (en) 2018-01-03
KR102630614B1 (ko) 2024-01-26
IL253815B (en) 2019-06-30
UA122405C2 (uk) 2020-11-10
ZA201705301B (en) 2025-02-26
BR112017018201A2 (pt) 2018-04-10
SG11201706849SA (en) 2017-09-28
RU2017127720A (ru) 2019-03-26
PH12017501519A1 (en) 2018-02-05

Similar Documents

Publication Publication Date Title
PH12017501519B1 (en) Radiopharmaceutical solutions with advantageous properties
SI3896064T1 (sl) 4,6-diamino-kinolin-3-karbonitrilni derivati kot modulatorji raka osaka thyroid (cot) za zdravljenje crohnove bolezni in ulceroznega kolitisa
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
ZA201708692B (en) Antibacterial compounds
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2020004075A (es) Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2017007550A (es) Composiciones microencapsuladas de cannabinoides.
MX2017000980A (es) Composiciones de tratamiento.
MX2017000976A (es) Composiciones de tratamiento.
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
PH12016501095A1 (en) Gabapentinoids and sigma receptor ligands combinations
PH12015502815A1 (en) Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps)
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
EA201690445A1 (ru) Лечение рака
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.
EA201690950A1 (ru) Средства и способ предотвращения миграции танина из древесины
PH12016502547A1 (en) Methods for treating infections
MX2017013669A (es) Composiciones para el tramiento del cancer.
MX2017011838A (es) Composiciones y metodos para tratar carcinoma hepatocelular.
MX378444B (es) Composiciones que inhiben a la enzima triosa fosfato isomerasa (tim) de trichomonas vaginalis para el tratamiento de la tricomoniasis.
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes

Legal Events

Date Code Title Description
FG Grant or registration